First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura.

CONCLUSION: Hetrombopag was well tolerated and preliminary efficacious. Efficacy, safety and PK data suggested that 7.5 mg hetrombopag once daily was the anticipated therapeutic dose of hetrombopag in CITP patients and have been recommended to investigate in the later confirmatory clinical study of hetrombopag.
PMID: 32865293 [PubMed - as supplied by publisher]

Source: Thrombosis and Haemostasis - August 30, 2020 Category: Hematology Authors: Wang Z, Chen L, Zhang F, Lu H, Chen X, Wen A, Luo J, Hu Y, Wang Y, Niu T, Zheng L Tags: J Thromb Haemost Source Type: research